A 12-wk, Rand., Double-blind, Double Dummy, Multi-ctr., Phase IV Study Comparing Efficacy and Safety of SYMBICORT pMDI 160/4.5 ug x 2 Actuations Twice Daily Versus Pulmicort (Budesonide Inhalation Powder DPI) 180 ug x 2 Inhalations Twice Daily, in Adult and Adolescent African American Subjects With Asthma

Trial Profile

A 12-wk, Rand., Double-blind, Double Dummy, Multi-ctr., Phase IV Study Comparing Efficacy and Safety of SYMBICORT pMDI 160/4.5 ug x 2 Actuations Twice Daily Versus Pulmicort (Budesonide Inhalation Powder DPI) 180 ug x 2 Inhalations Twice Daily, in Adult and Adolescent African American Subjects With Asthma

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Mar 2014

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Budesonide
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms Titan
  • Sponsors AstraZeneca
  • Most Recent Events

    • 04 Mar 2014 Results of a pooled analysis of this trial and another trial (see profile 700195498) presented at the 70th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 23 May 2012 Results presented at the 108th International Conference of the American Thoracic Society.
    • 10 May 2012 Safety results from this trial was consistent with that seen in a 52-week study (see profile 700020770), according to an AstraZeneca media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top